Results 131 to 140 of about 37,814 (299)
Clinical Interventions in Aging, 2013 Angie HC Fong,1 Timothy YY Lai1,2 1Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong; 22010 Retina and Macula Centre, Tsimshatsui, Kowloon, Hong Kong Abstract: Neovascular ...
Fong AH, Lai TY
doaj
Ranibizumab for idiopathic epiretinal membranes: A retrospective case series [PDF]
, 2013 PurposeTo study the effect of intravitreal ranibizumab on idiopathic epiretinal membranes (ERMs).MethodsA retrospective cohort study on a consecutive series of ranibizumab intravitreal injections for epiretinal membranes was performed.
Abouammoh, Marwan A. +4 more
core +1 more source
International Journal of Ophthalmology, 2014 AIM:To compare the efficacy and safety of combination of ranibizumab with photodynamic therapy (PDT) vs ranibizumab monotherapy in the treatment of age-related macular degeneration (AMD).METHODS:The Cochrane Central Register of Controlled Trials (CENTRAL)
Jun-Kang Si +9 more
doaj +1 more source
Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. [PDF]
, 2008 PURPOSE: To determine the incidence of and the risk factors for the development of retinal pigment epithelial (RPE) tears after intravitreal bevacizumab (Avastin) injection for the treatment of exudative age-related macular degeneration (AMD). METHODS: A
Brod, Roy +5 more
core +2 more sources
Clinical Ophthalmology, 2012 Patrick D Williams,1 David Callanan,1 Wayne Solley,1 Robert L Avery,2 Dante J Pieramici,2 Tom Aaberg31Texas Retina Associates, Dallas, TX, 2California Retina Consultants and Research Foundation, Santa Barbara, CA, 3Retinal Associates, Grand Rapids, MI ...
Williams PD +5 more
doaj
Graefe's Archive for Clinical and Experimental Ophthalmology, 2019 To compare treatment efficacy of anti-VEGF medications following pro re nata (PRN, “as needed”, monthly injections only in case of active disease) or treat and extend (T&E, progressive extension of treatment intervals up to 12 weeks depending on the ...
Michèle Augsburger, G. Sarra, P. Imesch
semanticscholar +1 more source
RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Retina, 2019 LUMINOUS study confirms the effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in real-world clinical practice.
F. Holz +11 more
semanticscholar +1 more source
Treatment Strategies for Refractory Diabetic Macular Edema: Switching Anti-VEGF Treatments, adopting corticosteroid-based treatments, and combination therapy [PDF]
, 2016 Introduction: The pathophysiology of diabetic macular edema (DME) is complex, involving vascular endothelial growth factor (VEGF) and other inflammatory mediators.
Ciulla, Thomas A., Hussain, Rehan M.
core +1 more source
Ranibizumab—The jury is still out [PDF]
Acta Paediatrica, 2020 Amy Keir, Amy Keir, Elizabeth Allen
openaire +3 more sources
Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration [PDF]
, 2018 Purpose: The aim of this work is to investigate the characteristics of eyes failing to maintain visual acuity (VA) receiving variable dosing ranibizumab for neovascular age-related macular degeneration (nAMD) after three initial loading doses. Methods: A
Ambresin, Aude +3 more
core